Among the most commonly asked questions about ipamorelin are "Is ipamorelin a steroid?", "Why can't my clinic write a prescription for ipamorelin any longer?", and "Does ipamorelin have any effects?". The answers are negative, a new regulation from the FDA taking effect in 2023, and finally, that ipamorelin actually has effects under certain limits. More about ipamorelin, its dosage, and its side effects is found in this article.
Assuming you already know that the blend format is mostly used in research protocols of your choice, the CJC-1295 / Ipamorelin Blend at US Peptide Labs is the right starting point. ipamorelin peptide library entry provides all information regarding the complete compound profile, including dosage references.
Ipamorelin is a synthetic pentapeptide or five amino acids that attaches to the ghrelin receptor (GHS-R1a) located inside the pituitary gland and the hypothalamus, and activates a burst of growth hormone. The drug was designed for Novo Nordisk and was noted first by Raun et al. The origin is also important in the sense that it is first of all research laboratory drug, as it is not a modifcation of an already-known medicine and is not a steroid chemically speaking.
Can we categorize ipamorelin as a steroid? It is not true, since steroids are substances that are made from lipids and consist of a structure of four carbon atoms. It is also known that ipamorelin is made from amino acids. The reason for this misunderstanding may be due to confusion on the forums, where these types of drugs are discussed together.
The role of ipamorelin is to stimulate the secretion of increased amounts of human growth hormone (GH) from the human pituitary gland rather than delivering exogenous GH. This is important because it informs us about the side effects produced by using different classes of GHRPs. As ipamorelin works through the feedback loops of the pituitary gland, the increases observed with some of the more established GHRPs (e.g., GHRP-2, GHRP-6, and hexarelin) in terms of the levels of cortisol, prolactin, and aldosterone hormone are not encountered when using ipamorelin.
The GH peak occurs within about 30-60 minutes of administration. The ipamorelin half-life is approximately 2 hours, and GH should return to baseline levels within about 3 hours. The reason the protocols suggest 1-3 doses of ipamorelin a day is because the short time window makes injection a good option while avoiding the inhibition effect an increase in insulin has on GH.
Ipamorelin is classified as a GHRP (growth hormone releasing peptide), rather than a GHRH analogue. It targets the ghrelin receptor while CJC-1295 works through the GHRH receptor. These two peptides work on two different receptor populations on somatotroph cells, which maximizes the GH pulse achieved when both are administered together. In this way, the CJC-1295 / Ipamorelin combination comes to exist. Please refer to the CJC-1295 library entry for a comprehensive overview of the GHRH aspect of the combination.
According to our honest account, the use of ipamorelin generates GH pulses in both animal and human models, as well as GH pulses having various results on body composition, recovery, and sleep architecture. In terms of ipamorelin clinical trial records in humans, we can say that they are limited and narrow due to which researchers have to base their assumptions on mostly animal studies.
Reported effects in the research literature, with the appropriate caveats on study type:
Amplicitud de pulso de GH: Probar que los estudios de farmacocinética en humanos fueron exitosos. Ipamorelin muestra un pulso de GH limpio y selectivo sin la elevación de cortisol o prolactina que aparece con dosis equivalentes de GHRP-6.
Lean mass and fat metabolism: Observations made in rodent models and drawing conclusions from the physiology of GH. GH works to stimulate lipolysis and promote nitrogen retention, though it is not known how effective this will be in humans as determined by clinical trials.
There is a close relationship between GH levels and deep sleep. Healthy adults experience the highest amount of GH within the first ninety minutes of falling asleep. This is why many practitioners choose to administer ipamorelin prior to bedtime. Although sleep researchers who utilized this procedure reported better sleep quality, there is no clinical study on that question. Please follow the peptides for sleep guide for more details about this topic.
Recovery and connective tissue: GH and IGF-1 have been shown to aid in collagen synthesis. Data from animal studies utilizing GHRPs suggest accelerated healing in tendon and cartilage models. There is no evidence available regarding ipamorelin in human subjects.
Digestive system movement following surgery: The original indication of Helsinn. Results from phase 2 were not fully released and the trial was halted.
After 30 to 60 minutes of injection, GH level in blood stream becomes peak and returns to its base level about 3 hours following injection – and this is acute pharmacokinetics. As for its further effects on body composition, rehab process, or sleep of research subjects they are recorded after prolonged use of the drug, which is contrary to common misconception that some results can be achieved in just a couple of days. There are no controlled before and after experiments with ipamorelin conducted on healthy humans.
Pharmacology is the same for both males and females. GHS-R1a density and pituitary GH-release capacity are present in males and females. Research protocols published in literature use body weight-based dosage (1 mcg/kg is also the commonly used norm) instead of dosage based on sex. Of note is the fact that women also show a higher baseline GH pulse frequency compared to men, which should be taken into account in understanding the observations made since the added effect of introducing a GHRP may not be significant in light of the higher baseline GH pulse frequency. By 2026, there has been no controlled trial of ipamorelin, which specifically looked at differences between sexes.
The Ipamorelin peptide will not lead to a rise in testosterone levels, promoting the function of the GH axis instead of the HPG axis and therefore, not triggering the release of LH, FSH or testosterone. Researchers often ask about this because they encounter forum discussions where GH peptides are incorrectly confused with anabolic substances.
The benchmark in the literature is 1 mcg per kilogram of bodyweight for every injection . Standard research protocols utilize 200-300 mcg subcutaneous in a day, 1-3 times, fasted . The table compares the 1 mcg/kg reference across different bodyweights and the corresponding amount from a given 5 mg pack (based on 2.5 ml bacteriostatic water, producing 2 mg/ml = 2000 mcg/ml) for the interactive version in the peptide dosage calculator .
| Bodyweight | Dose at 1 mcg/kg | Volume (2 mg/ml Solution) | Common Protocol Dose |
|---|---|---|---|
| 60 kg (132 lb) | 60 mcg. | 0.03 ml. | 200 mcg / 0.10 ml. |
| 75 kg (165 lb) | 75 mcg. | 0.038 ml. | 200 mcg / 0.10 ml. |
| 90 kg (198 lb) | 90 mcg. | 0.045 ml. | 250 mcg / 0.125 ml. |
| 110 kg (242 lb) | 110 mcg. | 0.055 ml. | 300 mcg / 0.15 ml. |
The full ipamorelin dosage reference, including the blend math, is at getuspeptides.com/peptide-dosage/ipamorelin/ .
Fasted administration is the common factor in almost every protocol. High insulin will inhibit GH release from the pituitary gland, making administering the drug while fed alter the expected outcome. The three most common injection windows used in research protocols are: on waking (fasted), 30 to 45 minutes before fasted workout, and right before sleep (at least two hours after the last meal). The preferred route for the subcutaneous injections is the abdomen or thigh.
Protocols found in published studies do not distinguish dosages based on gender; instead, they differentiate based on body weight. The lower dosage of 200 mg and the higher dosage of 300 mg are figures that occur most frequently in study protocols and are practical dosages since they tend to apply to the majority of adult body weights, giving either 1 mg or 2 mg per kilogram of body weight. Some protocols in muscle-building studies do use the maximum total dosage of 300 mg in three doses, but this dosage is at the highest level of what has been reported in the literature, and there is no evidence to indicate that ipamorelin has been studied for safety regarding increasing dosages.
The typical cycle of drugs that have been studied and are used in the medical establishment is between eight and twelve weeks. However, specific data on continuous use exceeding twelve weeks for ipamorelin has never been published. Continued use of GH secretagogues leads to speculative risks of desensitization of the pituitary gland and accumulation of IGF-1 which has not been investigated in the human studies of this subject. The customary amount of time to refrain from use of drugs between cycles is four weeks, but there is no evidence indicating this period as a necessity.
To reconstitute: The lyophilized powder comes in a vial; take 1-3 ml of bacteriostatic water and pour it into the vial without allowing the water to directly hit the powder. Mix gently; do not shake! The reconstituted vial should then be kept at 2-8 degrees Celsius (in a normal fridge). Lyophilized powders must be stored under cold, dry and dark conditions (in a refrigerator or room temperature freezer) prior to reconstitution. The peptide dosage calculator will do the necessary calculations for finding the correct amount of volume in whatever vial size might be used.
Lyophilized powder vials, including doses of 2 mg, 5 mg, and 10 mg, as well as CJC-1295/ipamorelin blend vials and nasal sprays, make up the various formulations of Ipamorelin. The oral formulation for Ipamorelin has not been developed. The following table summarizes the available formulations for research purposes.
| Format | Bioavailability | Notes |
|---|---|---|
| Subcutaneous Injection (lyophilized vial) | High; direct systemic delivery. | Standard research format; most protocol data is based on this route. |
| CJC-1295 / Ipamorelin Blend Vial | High (same route). | Two-receptor mechanism; most common format in current research catalogs. |
| Nasal Spray Blend | Lower and more variable than SC injection. | Non-injection option; bioavailability data for peptides via nasal route is limited. |
| Oral (capsules, pills, troches) | Not established; peptides are degraded in the GI tract. | No oral ipamorelin form with demonstrated bioavailability exists in the research literature. |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
For researchers who want to avoid injections, the <a href="https://uspeptidelabs.co/products/cjc-1295-ipamorelin-nasal-spray" style="color: #1a1a1a; font-weight: 500;">CJC-1295 / Ipamorelin Nasal Spray at $188.00</a> from US Peptide Labs is an option. The one caveat is the bioavailability limitation.
</p>
The side effects associated with ipamorelin are seen generally as being mild as compared with older forms of the GHRP, but this does not imply ipamorelin does not have side effects associated with its use. The distinct way that ipamorelin acts on GHS-R1a makes it different from other GHRPs like GHRP-2, GHRP-6 and hexarelin because it does not stimulate the secretion of cortisol and prolactin in an important manner.
| Side Effect | Mechanism / Timing | Notes |
|---|---|---|
| Hunger | GHS-R1a is the ghrelin receptor; activation stimulates appetite. | Onset 30-60 minutes post-injection; a very well-established property. |
| Flushing and Warmth | Vascular response. | Brief; typically resolves within 20-30 minutes of injection. |
| Headache | Likely tied to GH pulse rather than ipamorelin itself. | Reported in some subjects. |
| Injection-Site Reaction | Local irritation. | Redness, mild swelling. Standard for subcutaneous peptide injection. |
| Water Retention | GH drives sodium and water retention. | Usually temporary during the first weeks of a program. |
| Tingling in Extremities | Possible fluid shift or carpal tunnel-like pressure from water retention. | Reported in some subjects. |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
Ipamorelin does not appear to elevate <span style="color: #1a1a1a; font-weight: 600;">cortisol, prolactin, aldosterone, blood sugar or testosterone</span> at research doses. Long-term human data on GH secretagogues is limited - a real gap in the literature, not an absence of concern.
</p>
Several variables always lead to diminished or absent effects in GH-secretagogue protocols. The most frequent cause is the injection in the fed state: increased insulin levels prevent GH secretion from the pituitary gland, thus affecting the given stimulus. Even if the subject eats within 2 hours from the injection, the effect is deemed insufficient.
Storage errors rank as the second most frequent issue. Vials containing reconstituted substrates must be maintained at 2-8 C. Lyophilized powder should be kept cool, dry and protected from light. A vial stored at room temperature for a long time or subject to multiple freeze-thaw cycles could lead to degradation of the peptide, and thus a ceased GH response.
It is also good practice to validate calculations in blend vials. The blend of CJC-1295 / Ipamorelin from US Peptide Labs contains both compounds in amounts of 7.5 mg and 10 mg, respectively. The concentration of ipamorelin in the vials is nowhere near the value of 5 mg if the compound comes in its own vial with 2.5 ml of fluid. The best starting point is calculating the concentrations as per the COA (certificate of analysis).
In addition to protocol coding variables, hyperthyroidism and chronic hyperinsulinemia (whether from diet or insulin resistance) both result in baseline suppression of the GH axis. These are physiological factors that cannot be altered by any dosage or administration.
The FDA has not given ipamorelin approval for any indication. It has never successfully completed a new drug application either. Novo Nordisk conducted pharmacology research on it while the Helsinn postoperative ileus program reached phase 2 and got terminated in 2013 without becoming approved. Thus, as of 2026, there is no approved ipamorelin medication in the U.S. or in the EU or any other major regulatory authority.
In order to obtain FDA approval a drug must have completed phase 3 clinical trials, must have a specific indication for use and must have a commercial partner who is willing to finance the process. At this time none of those conditions exist for ipamorelin. Among the three comparably used GH-axis peptides – ipamorelin, sermorelin and tesamorelin – only tesamorelin is currently approved by the FDA (as Egrifta for HIV-associated lipodystrophy).
Ipamorelin is in the U.S. legally available for laboratories as a research substance but it is not currently under any schedule of the DEA. The purchase for personal use is different from research use and that is why it is delivered by serious suppliers with a label of being intended for research only use.
For the competitive athlete, the scenario is entirely different. Ipamorelin, according to the WADA Prohibited List, is disallowed at all times and falls under the S2 of Peptide Hormones, Growth Factors, Related Substances, and Mimetics, specifically classified under S2.2 with regard to growth hormone secretagogues. The NCAA prohibits use of ipamorelin in similar line with WADA rules on GH secretagogues. Throughout testing for anti-doping purpose, any athlete must consider ipamorelin banned irrespective of how it has been Wall Street Journal.
In many scientific studies and clinical applications, ipamorelin, sermorelin and tesamorelin are sometimes categorized as GH-releasing peptides since all of them impact GH secretion. Nevertheless, each of these synthetic substances acts in a different way to affect secretion of GH and has its own distinct history of approvals for human use. Out of these three peptides, tesamorelin is the only one that has been approved by FDA (Egrifta for treatment of HIV-associated lipodystrophy). Sermorelin used to be FDA approved too (as Geref) but this approval was withdrawn after cessation of production of this peptide. Last but not least, the use of ipamorelin has never received FDA approval.
| Feature | Ipamorelin | Sermorelin | Tesamorelin |
|---|---|---|---|
| Class | GHRP / ghrelin receptor agonist. | GHRH analog (1-29 fragment). | GHRH analog (full sequence, stabilized). |
| Receptor | GHS-R1a. | GHRH receptor. | GHRH receptor. |
| Half-Life | ~2 hours. | ~11-12 minutes. | ~26 minutes. |
| FDA Status | Not approved; 503A Category 2. | Not currently approved (Geref withdrawn). | Approved (Egrifta, HIV lipodystrophy). |
| Common Research Dose | 200-300 mcg SC, 1-3x/day. | 200-300 mcg SC, nightly. | 2 mg SC, once daily. |
| Cortisol / Prolactin Effect | Minimal at standard doses. | Minimal. | Minimal. |
| Often Combined With | CJC-1295 (GHRH). | GHRP-2 or ipamorelin. | Used alone (approved indication). |
<p style="font-family: 'Arial', sans-serif; font-size: 14px; color: #1a1a1a; margin: 20px 0; line-height: 1.6;">
Sermorelin dosing details sit at <a href="https://getuspeptides.com/peptide-dosage/sermorelin/" style="color: #1a1a1a; font-weight: 500;">getuspeptides.com/peptide-dosage/sermorelin/</a>, and the tesamorelin profile is at <a href="https://getuspeptides.com/peptide-library/tesamorelin/" style="color: #1a1a1a; font-weight: 500;">getuspeptides.com/peptide-library/tesamorelin/</a>. US Peptide Labs carries <a href="https://uspeptidelabs.co/products/tesamorelin" style="color: #1a1a1a; font-weight: 500;">Tesamorelin 10 mg at $92.00</a> for direct comparison between the two peptides.
</p>
What I find interesting is the fact researchers rarely ask about switching from one product to the other, as the half-life difference between the products, in this case, sermorelin and ipamorelin is great enough to be relevant as it pertains to protocol development. Because of the short half-life of sermorelin, it is necessary to inject it close to the GH window, while ipamorelin has a significantly longer half-life, allowing it to be injected over a longer time span before the desired effect is achieved.
As of late 2026, US Peptide Labs does not offer ipamorelin on its own. The ipamorelin currently offered is the CJC-1295 / Ipamorelin Blend, 7.5 mg / 10 mg, 10 ml vial, at $112.00 product. With 99.5% purity verified by AxisPharm, the product comes with a lot-specific Certificate of Analysis (COA), which can be found at uspeptidelabs.co/pages/quality-coas. More information on interpreting the Certificate of Analysis is available on the COA reading guide website, which explains concepts like purity by HPLC, effects of mass spectrometry and the importance of testing for endotoxins.
The blended format is not a solution to the absence of a single SKU, rather it is the format that has been used for most of the research protocols since the two receptor mechanism produces more growth hormone pulse than any single peptide. Pricing in bulk: 2 and more units cost $106.40, five or more cost $100.80. Free delivery in the United States on orders over $70, the product is shipped from the U.S. warehouse with tracking information provided. The purchaser has to be over 21 years of age.
The full performance and vitality collection is at uspeptidelabs.co/collections/performance-vitality .
In the field of research, ipamorelin has been utilized to examine GH pulse mechanisms, the effects of GH stimulation on body composition, sleep patterns, and rehabilitation. As far as clinical uses are concerned, the drug was researched as a treatment for postoperative ileus (Helsinn, phase 2, discontinued in 2013) but was not approved for any use. Currently, there is no permission for any therapeutic applications.
According to literature protocols, dose administration is in doses of 200-300 mcg in subcutaneous injections, at 1-3 times per day while in a fasted state. The literature benchmark for dosing is 1 mcg/kg bodyweight per injection. Timing windows include the fasted morning, pre-training (fasted), and pre-sleep (2+ hours after the last meal).
In the event that GH is injected into the body, it is seen that the maximum effect of GH is experienced in 30-60 minutes after the injection. After peak GH activity, there will be a return to normality within 3 hours. However, it will take many weeks or months of repeated treatments in order to report a change in terms of body composition, recovery and sleep in subjects of the study, rather than just a couple of days. There is no such evidence available currently to back any claims regarding ipamorelin’s effect in healthy human beings using any controlled study.
There is no conclusive evidence connecting ipamorelin to cancer in the existing scientific publications. Theoretical alarm is associated with IGF-1, as the long-term increase in IGF-1 from any source of GH stimulation has potential risks, based on the sources related to GH-like treatment. Unlike other GH-stimulating agents, ipamorelin has no effect on the amount of IGF-1 directly or otherwise bypassing the feedback from the pituitary gland. Its influence on the IGF-1 levels when using research doses is substantially lesser than that of GH. Moreover, there is an absence of any long-term safety human studies on ipamorelin in the scientific publications which need to be acknowledged in any future research projects.
No. Ipamorelin has never been approved by the FDA for any use, nor has it received clearance from any major regulatory body. It is listed as a 503A Category 2 substance, meaning compounding pharmacies cannot prepare it for the use of patients. Of the three GH-axis peptides that are most often compared, namely ipamorelin, sermorelin and tesamorelin, only tesamorelin is currently FDA approved (under the trade name Egrifta for HIV-related lipodystrophy).
The main classification difference is in receptor type. On the one hand, Ipamorelin is known as a GHRP, activating the ghrelin receptor (GHS-R1a). On the other hand, Sermorelin is classified as a GHRH analog, activating GHRH receptors through a different mechanism of action. Different mechanisms are what makes it possible to use both substances in protocol combination, just as in the case with CJC-1295/ipamorelin combination. The half-life of ipamorelin equals roughly 2 hours. Half-life of sermorelin equals roughly 11 minutes. Neither of drugs is approved for prescription in the USA. Full sermorelin profile: getuspeptides.com/peptide-library/sermorelin/ .
For the researchers seeking to procure the fusion compound, the CJC-1295 / Ipamorelin Blend at US Peptide Labs - 99.5% HPLC purity, COA tailored to the lot, costing $112.00 with free shipping in the United States for orders surpassing the $70 figure - is the most prominent choice of ipamorelin available in the catalog. Note that all purchases are carried out for laboratory research purposes only and are addressed to customers over the age of 21.